(Q35295368)

7 August 2017

title

Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer (English)

1 reference

7 August 2017

Maria E Cabanillas

1

1 reference

7 August 2017

Mimi I Hu

series ordinal

2

1 reference

7 August 2017

Jean-Bernard Durand

series ordinal

3

1 reference

7 August 2017

Naifa L Busaidy

series ordinal

4

1 reference

7 August 2017

publication date

4 October 2011

1 reference

Journal of Thyroid Research

7 August 2017

published in

1 reference

7 August 2017

volume

2011

1 reference

7 August 2017

page(s)

985780

1 reference

Creative Commons Attribution 3.0 Unported

7 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Pazopanib: Clinical development of a potent anti-angiogenic drug

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Home blood pressure monitoring in clinical practice: a review

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Phase II trial of sorafenib in metastatic thyroid cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Mechanisms of adverse effects of anti-VEGF therapy for cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Sorafenib in advanced clear-cell renal-cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Angiogenic growth factors and hypertension

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Polycythemia vera: myths, mechanisms, and management

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

The microcirculation and hypertension

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3189619

Mechanisms of hypertension associated with BAY 43-9006.

12 July 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

RAF inhibition and induction of cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F985780

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22007339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22007339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4061/2011/985780

1 reference

7 August 2017

1 reference

7 August 2017

1 reference